Although “everybody wants to use the new technology” when it comes to incorporating circulating tumor DNA (ctDNA) monitoring into community oncology care, “It’s challenging,” says Lalan Wilfong, MD, a medical oncologist with Texas Oncology and senior vice president of value-based care at Thyme Care.
Speaking at the Community Oncology Alliance (COA) 2025 Community Oncology Conference, Dr. Wilfong describes his personal experience using ctDNA to help guide patient care while acknowledging that “we don’t really truly understand the best way of utilizing it in clinical practice at this point.” He outlines the key questions that must be addressed for increased uptake and also looks to the “explosion of new therapeutics” coming to community cancer care soon.